IP Library Granted Patent US 8,697,844
Granted Patent B2
US 8,697,844 · App. 13/509,867 · Granted Apr 15, 2014

Method of purifying pegylated proteins

Inventors: Matthias Karl Dietrich Wiendahl (Hilleroed, DK); Lars Sejersgaard (Albertslund, DK); Are Bogsnes (Nivaa, DK)
Assignee: Novo Nordisk A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,844
App. No.
13/509,867
Granted
Apr 15, 2014
Kind
B2
Abstract

The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Claims (11)

1. A method for purifying a PEGylated protein which comprises performing anion exchange chromatography with an elution buffer, characterized in that said chromatography comprises an impurity removal step prior to elution wherein said impurity removal step comprises washing said anion exchange column with an acidic buffer at a pH of between 3.9 and 4.5, wherein the PEGylated protein is selected from the group consisting of Factor II (FII), Factor VII (FVII), Factor IX (FIX), Factor X (FX), protein S and protein C.

2. The method of claim 1 , wherein said impurity is ST3 beta-galactoside alpha-2,3-sialyltransferase 3 (ST3Gal3).

3. The method of claim 1 , wherein the impurity removal step comprises washing with an acidic buffer at a pH of selected from the group consisting of between 4.0 and 4.5 and between 4.0 and 4.4.

4. The method of claim 1 , wherein the acidic buffer comprises sodium acetate or acetic acid, wherein the concentration of sodium acetate is about 50 mM, and wherein the concentration of acetic acid is about 140 mM.

5. The method of claim 1 , wherein an equilibration step is performed prior to the acidic wash step.

6. The method of claim 5 , wherein the equilibration step comprises application of an equilibration buffer at a pH of between 5 and 7.

7. The method of claim 5 , wherein the equilibration buffer comprises sodium acetate and acetic acid, wherein the concentration of acetic acid is about 10 mM, and wherein the concentration of sodium acetate is about 90 mM sodium.

8. The method of claim 1 , wherein the PEGylated protein is selected from the group consisting of Factor IX (FIX) and Factor VII (FVII).

9. The method of claim 1 , wherein the anion exchange material comprises HQ.

10. The method of claim 9 , wherein the HQ anion exchange material comprises Poros® HQ.

11. The method of claim 9 , wherein the HQ anion exchange material comprises Poros® 50 HQ.

Assignments (4)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 15, 2021
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 058122/0546 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT PREVIOUSLY RECORDED ON REEL 035134 FRAME 0102. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTION OF CONVEYING PARTY FROM NOVO NORDISK HEALTHCARE AG TO NOVO NORDISK A/S. Recorded Mar 12, 2015
From: NOVO NORDISK A/S
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 035186/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2015
From: NOVO NORDISK HEALTHCARE AG
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 035134/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2012
From: WIENDAHL, MATTHIAS KARL DIETRICH; SEJERSGAARD, LARS; BOGSNES, ARE
To: NOVO NORDISK A/S
Reel/Frame 028376/0018 →
Priority Claims (1)
EP 09176881 · Nov 24, 2009 · regional
Continuity (2)
Provisional Application 61264486 · Nov 25, 2009
Related Publication 20120244137A1 · Sep 27, 2012